EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial

Martina Chiriacò, Domenico Tricò, Alberto Giannoni, Luca Sacchetta, Lorenzo Nesti, Simona Baldi, Tiziana Scozzaro, Vincenzo Castiglione, Andrea Natali, Ele Ferrannini

Diabetologia · 2026-07 · 69 (7) · 1806-1817

DOI: 10.1007/s00125-026-06705-6 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetologia, online erschienen am 12.03.2026. Verfasst von Martina Chiriacò und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. martina.chiriaco@med.unipi.it. Hauptthemen laut MEDLINE: Canagliflozin, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Sodium, Dietary. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiovascular and renal protection in type 2 diabetes and chronic kidney disease (CKD). Although both excess and restricted sodium intake are linked to adverse outcomes, the interaction of sodium intake with SGLT2 inhibitors has not been explored. This study aimed to examine how dietary sodium intake affects cardiorenal outcomes and whether canagliflozin modifies these effects. METHODS: A post hoc analysis of the CREDENCE trial (median follow-up 2.6 years) was conducted in individuals with type 2 diabetes and CKD randomised to canagliflozin 100 mg or placebo. Using a validated formula, we estimated daily sodium intake from urine in 2573 participants, divided into low-normal sodium (LNS; n=1286) and high sodium (HS; n=1287) groups. Outcomes included the following: cardiovascular death or hospitalisation for heart failure; heart failure alone; a composite renal outcome; and all-cause death. Cox models were adjusted for confounders. Sodium intake was additionally analysed as a continuous variable to assess non-linearity. RESULTS: In the placebo group, LNS intake increased the risk of heart failure/cardiovascular death vs HS (adjusted HR [adjHR] 1.56 [95% CI 1.10, 2.23]). Canagliflozin significantly reduced this risk in the LNS group (adjHR 0.48 [95% CI 0.33, 0.70]) but not in the HS group (adjHR 1.05 [95% CI 0.73, 1.53]). Similar patterns were seen for heart failure alone. Sodium intake had no effect on renal outcomes, while canagliflozin reduced renal risk in both the LNS group and the HS group. Neither sodium intake nor canagliflozin influenced all-cause mortality. Continuous modelling revealed a near-linear rise in heart failure/cardiovascular death risk as sodium intake decreased in placebo recipients, while this gradient was flattened with canagliflozin. CONCLUSIONS/INTERPRETATION: In individuals with type 2 diabetes and CKD, LNS intake increases the risk of heart failure and cardiovascular death, while renal outcomes are unaffected by sodium intake. Canagliflozin mitigates the increased cardiovascular risk in individuals with LNS intake, while offering renal protection irrespective of dietary sodium. TRIAL REGISTRATION: Clinicaltrial.gov NCT02065791.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsSodium, DietaryHumansFemaleMaleMiddle AgedAgedHeart FailureRenal Insufficiency, Chronic

Stichwörter der Autor:innen

Chronic kidney diseaseDiabetesHeart failureSodium

Substanzen

CanagliflozinSodium-Glucose Transporter 2 InhibitorsSodium, Dietary

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. martina.chiriaco@med.unipi.it.
  • Laboratory of Metabolism, Nutrition, and Atherosclerosis, University of Pisa, Pisa, Italy. martina.chiriaco@med.unipi.it.
  • Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy. martina.chiriaco@med.unipi.it.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Laboratory of Metabolism, Nutrition, and Atherosclerosis, University of Pisa, Pisa, Italy.
  • Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.

Förderung

  • Janssen Research and Development

Zitieren

APA

Chiriacò, M., Tricò, D., Giannoni, A., Sacchetta, L., Nesti, L., Baldi, S., Scozzaro, T., Castiglione, V., Natali, A., & Ferrannini, E. (2026). Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial. Diabetologia, 69(7), 1806-1817. https://doi.org/10.1007/s00125-026-06705-6

Vancouver

Chiriacò M, Tricò D, Giannoni A, Sacchetta L, Nesti L, Baldi S, et al. Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial. Diabetologia. 2026;69(7):1806-1817. doi:10.1007/s00125-026-06705-6

BibTeX
@article{Chiriac2026,
  author = {Chiriacò, Martina and Tricò, Domenico and Giannoni, Alberto and Sacchetta, Luca and Nesti, Lorenzo and Baldi, Simona and Scozzaro, Tiziana and Castiglione, Vincenzo and Natali, Andrea and Ferrannini, Ele},
  title = {Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial},
  journal = {Diabetologia},
  year = {2026},
  volume = {69},
  number = {7},
  pages = {1806--1817},
  doi = {10.1007/s00125-026-06705-6}
}
Kostenlos starten →